Early-stage respiratory syncytial virus (RSV) vaccine trial begins

(NIH/National Institute of Allergy and Infectious Diseases) The National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, has launched a clinical trial of an investigational vaccine designed to protect against respiratory syncytial virus (RSV). The Phase 1 study will enroll a small group of healthy adult volunteers to examine the safety of an experimental intranasal vaccine and its ability to induce an immune response. The study is being conducted at the Cincinnati Children's H...